| Poly (ADP-ribose) polymerase inhibitors as cancer therapy JF Hilton, MJ Hadfield, MT Tran, GI Shapiro Front Biosci 18, 1392-1406, 2013 | 29 | 2013 |
| Advances in liquid biopsy technology and implications for pancreatic cancer AG Raufi, MS May, MJ Hadfield, AA Seyhan, WS El-Deiry International journal of molecular sciences 24 (4), 4238, 2023 | 19 | 2023 |
| Pharmacist intervention in colorectal cancer screening initiative LM Holle, J Levine, T Buckley, CM White, C White, MJ Hadfield Journal of the American Pharmacists Association 60 (4), e109-e116, 2020 | 15 | 2020 |
| Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies MJ Hadfield, R Helsing, JM Grant-Kels Melanoma Research 30 (5), 429-432, 2020 | 8 | 2020 |
| Antiphospholipid Syndrome Presenting With Splenic Infarct MJ Hadfield, JR Thumar JCR: Journal of Clinical Rheumatology 27 (1), e19, 2021 | 5 | 2021 |
| Hyperprogression in PDL1 expressive, recurrent gastroesophageal-junction adenocarcinoma after pembrolizumab S Sama, MJ Hadfield, NL Lia, J Vredenburgh Cureus 11 (6), 2019 | 5 | 2019 |
| Updates in the treatment of non-metastatic castrate-resistant prostate cancer: the benefit of second-generation androgen receptor antagonists MJ Hadfield, V Lyall, LM Holle, M Dennison Annals of Pharmacotherapy 57 (11), 1302-1311, 2023 | 4 | 2023 |
| A fatal case of Immune thrombocytopenia secondary to the immune checkpoint inhibitor ipilimumab in a patient with BRAF wild type metastatic melanoma MJ Hadfield, G Mui Journal of Oncology Pharmacy Practice 26 (6), 1530-1532, 2020 | 4 | 2020 |
| Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R MJ Hadfield, A Turshudzhyan, K Shalaby, A Reddy Journal of Oncology Pharmacy Practice, 10781552211057867, 2021 | 3 | 2021 |
| A rare case of clear cell adenocarcinoma of the cervix with no intrauterine diethylstilbestrol exposure VM Thomas, SA Alexander, MJ Hadfield, J Vredenburgh Cureus 12 (4), 2020 | 3 | 2020 |
| Harnessing artificial intelligence for prostate cancer management L Zhu, J Pan, W Mou, L Deng, Y Zhu, Y Wang, G Pareek, E Hyams, ... Cell Reports Medicine, 2024 | 2 | 2024 |
| Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma A Turshudzhyan, M Hadfield, J Grant-Kels Melanoma Research 31 (5), 421-425, 2021 | 2 | 2021 |
| Amyloid deposition of the bilateral ureters in a patient with chronic systemic AL amyloidosis MJ Hadfield, V Lyall, B Ristau, V Patel, J Hundal, H Kennedy, J Thumar Urology 146, e10-e11, 2020 | 2 | 2020 |
| Neurologic complications of melanoma JV Cohen, N Wang, VA Venur, MJ Hadfield, DP Cahill, K Oh, ... Cancer 126 (3), 477-486, 2020 | 2 | 2020 |
| Case of anthracycline-induced cardiogenic shock: a call to optimize modifiable cardiac risk factors prior to chemotherapy A Gabriel, B Stringer, MJ Hadfield, M Madady Cureus 11 (6), 2019 | 2 | 2019 |
| Abnormal loss of weight R Pettitt, SV Kota, I OMS, M Hadfield, OMS II Osteopathic Family Physician 9 (2), 2017 | 2 | 2017 |
| The evolving posology and administration of immune checkpoint inhibitors: Subcutaneous formulations MJ Hadfield, DJ Benjamin, J Krell, J Warner, MP Lythgoe Trends in Cancer, 2024 | 1 | 2024 |
| Who goes first? Patterns of cancer drug approvals across four major regulatory authorities: EMA, FDA, Health Canada, and PMDA. JL Warner, S Mishra, MJ Hadfield, B Gyawali, A Cowan, AR Khaki, ... JCO Oncology Practice 19 (11_suppl), 149-149, 2023 | 1 | 2023 |
| Molecular and immune analysis of adrenocortical carcinoma (ACC): Implications for immune checkpoint inhibition (ICI). B Nazha, N Gandhi, AR Naqash, MJ Hadfield, T Zhuang, JT Brown, ... Journal of Clinical Oncology 41 (16_suppl), e16617-e16617, 2023 | 1 | 2023 |
| Abstract CT158: BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) MJ Hadfield, A De Souza, D Golijanin, R Wood, A Olszewski, SL Holder, ... Cancer Research 83 (8_Supplement), CT158-CT158, 2023 | 1 | 2023 |
Lisa HolleClinical Professor, University of ConnecticutVerified email at uconn.edu
